Guggenheim assumed coverage on shares of HilleVax (NASDAQ:HLVX – Get Rating) in a research report issued to clients and investors on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.
HLVX has been the subject of several other research reports. JPMorgan Chase & Co. started coverage on shares of HilleVax in a research report on Tuesday. They set an “overweight” rating for the company. Stifel Nicolaus initiated coverage on HilleVax in a research note on Tuesday. They set a “buy” rating on the stock.
NASDAQ HLVX opened at $9.50 on Tuesday. HilleVax has a 12 month low of $9.00 and a 12 month high of $20.95.
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- CrowdStrike: A Cybersecurity Unicorn
- Time to Bid Low for Farfetch Stock
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Texas Roadhouse Stock Looks Sizzling Down Here
- Don’t Wait Too Long to Buy These 3 Mega Caps
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.